The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years’ experience at a single centre

Abstract The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of tre...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical neuroscience 2011-03, Vol.18 (3), p.329-333
Main Authors: Parkinson, Jonathon F, Afaghi, Vahid, Payne, Cathy A, Buckland, Michael E, Brewer, Janice M, Biggs, Michael T, Little, Nicholas S, Wheeler, Helen R, Cook, Raymond J, McDonald, Kerrie L
Format: Article
Language:English
Subjects:
Adult
Aged
Anaplastic oligodendroglioma
Brain Neoplasms - genetics
Brain Neoplasms - mortality
Brain Neoplasms - pathology
Chemosensitivity
Chemotherapy
Chemotherapy, Adjuvant
Chromosomes, Human, Pair 1 - genetics
Chromosomes, Human, Pair 19 - genetics
Drug Resistance, Neoplasm - genetics
Female
Glioma
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Loss of Heterozygosity
Male
Middle Aged
Neurology
Oligodendroglioma
Oligodendroglioma - genetics
Oligodendroglioma - mortality
Oligodendroglioma - pathology
Prognosis
Proportional Hazards Models
Survival
Tumor Suppressor Protein p53 - metabolism
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs . 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p = 0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs . 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.
ISSN:0967-5868
1532-2653
DOI:10.1016/j.jocn.2010.07.101